Table 3.

Treatment-emergent AEs by cohort, grades 3 and 4, in ≥10% of patients

	Cohort 1	Cohort 2	Cohort 3	Cohort 3A	Cohort 4	Cohort 5	Cohort 5A	Total
	RO 0.30 mg/kg + Venetoclax 400 mg, n (%)	RO 0.45 mg/kg + Venetoclax 400 mg, n (%)	RO 0.45 mg/kg + Venetoclax 600 mg, n (%)	RO 0.45 mg/kg + Venetoclax 600 mg + Rituximab 375 mg/m2, n (%)	RO 0.45 mg/kg + Venetoclax 800 mg, n (%)	RO 0.65 mg/kg + Venetoclax 600 mg, n (%)	RO 0.65 mg/kg + Venetoclax 600 mg + Rituximab 375 mg/m2, n (%)
Patients, n	3	6	9	7	4	4	6	39
Neutropenia	1 (33.3)	1 (16.7)	5 (55.6)	1 (14.3)	0	2 (50.0)	1 (16.7)	11 (28.2)
Anemia	0	3 (50.0)	1 (11.1)	1 (14.3)	1 (25.0)	2 (50.0)	1 (16.7)	9 (23.1)
Thrombocytopenia	0	2 (33.3)	2 (22.2)	2 (28.6)	0	2 (50.0)	1 (16.7)	9 (23.1)
Hypokalemia	0	0	0	1 (14.3)	1 (25.0)	0	3 (50.0)	5 (12.8)
Febrile Neutropenia	0	1 (16.7)	2 (22.2)	0	0	0	1 (16.7)	4 (10.3)